Profile data is unavailable for this security.
About the company
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd a China-based company principally engaged in the independent research and development and customized research and development and production of peptide drugs and small molecule drugs. The Company's main business includes customized product business and independently selected product business. Its customized product business includes CDMO (Contract Development and Manufacturing Organization) business, technical service CRO (Contract Research Organization) and transfer business. Its independently selected product business focuses on small molecule chemical drugs and conducts drug research and development in the key treatment areas of diabetes, cardiovascular diseases, tumors and other diseases. The Company mainly operates its businesses in the domestic market and overseas markets.
- Revenue in CNY (TTM)1.90bn
- Net income in CNY498.69m
- Incorporated2009
- Employees2.03k
- LocationJiangsu Sinopep Allsino Biopharmaceutical Co Ltd#28 Linpu RoadEconomic Technology Development ZoneLIANYUNGANG 311121ChinaCHN
- Phone+86 57 186297893
- Fax+86 57 186298631
- Websitehttps://www.sinopep.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chongqing Genrix Biophrmctcl Co Ltd | 225.16m | -583.52m | 10.41bn | 743.00 | -- | 5.82 | -- | 46.22 | -1.59 | -1.59 | 0.6141 | 4.88 | 0.0712 | 0.3088 | 10.33 | 303,044.90 | -18.45 | -- | -19.95 | -- | 90.99 | -- | -259.16 | -- | 7.37 | -- | 0.3694 | -- | 2,384.11 | -- | 0.5049 | -- | -- | -- |
| Liaoning Chengda Biotechnology Co Ltd | 1.47bn | 177.94m | 10.67bn | 1.81k | 59.19 | 1.14 | -- | 7.26 | 0.433 | 0.433 | 3.56 | 22.54 | 0.1482 | 0.6786 | 1.24 | 813,192.10 | 1.79 | 8.07 | 1.86 | 8.36 | 79.03 | 84.98 | 12.11 | 35.75 | 19.28 | -- | 0.0013 | 44.77 | -4.22 | -0.0082 | -26.42 | -13.26 | -4.72 | -- |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.90bn | 498.69m | 10.68bn | 2.03k | 21.17 | 3.43 | -- | 5.62 | 1.60 | 1.60 | 6.13 | 9.84 | 0.3413 | 0.9306 | 3.06 | 936,748.90 | 8.90 | 7.19 | 13.04 | 9.67 | 66.64 | 59.30 | 26.08 | 20.28 | 0.928 | 16.07 | 0.4604 | 35.89 | 57.21 | 34.33 | 148.19 | 52.76 | 31.58 | -- |
| Aurisco Pharmaceutical Co Ltd | 1.62bn | 424.54m | 10.78bn | 1.78k | 25.08 | 4.24 | -- | 6.63 | 1.06 | 1.06 | 4.07 | 6.26 | 0.4188 | 1.09 | 4.41 | 910,578.10 | 10.94 | 11.37 | 12.60 | 13.29 | 59.77 | 52.93 | 26.13 | 22.34 | 3.01 | 635.15 | 0.2806 | 31.53 | 16.89 | 20.47 | 22.59 | 13.77 | 49.45 | -- |
| Chengdu Olymvax Biopharmaceuticals Inc | 709.13m | 64.21m | 11.01bn | 470.00 | 170.94 | 11.47 | -- | 15.52 | 0.1587 | 0.1587 | 1.75 | 2.36 | 0.3883 | 0.654 | 1.19 | 1,508,792.00 | 3.45 | 3.25 | 5.00 | 4.81 | 92.66 | 93.62 | 8.88 | 8.11 | 1.42 | 8.30 | 0.2906 | 7.39 | 18.69 | 26.88 | 18.24 | -- | 48.00 | -- |
| Shanghai Yizhong Pharmaceutical Co Ltd | 247.05m | 22.96m | 11.02bn | 65.00 | 471.02 | 7.54 | -- | 44.60 | 0.1132 | 0.1132 | 1.22 | 7.07 | 0.163 | 0.9556 | 2.26 | 3,800,801.00 | 1.51 | 5.44 | 1.58 | 5.64 | 81.39 | 92.99 | 9.30 | 36.90 | 7.84 | -- | 0.00 | 32.30 | -51.83 | -- | -95.68 | -- | 10.96 | -- |
| Cansino Biologics Inc | 971.83m | -142.03m | 11.23bn | 1.11k | -- | 2.99 | -- | 11.55 | -0.5455 | -0.5455 | 3.92 | 21.37 | 0.1271 | 0.5861 | 1.38 | 879,482.50 | -1.86 | -4.08 | -2.29 | -5.38 | 78.80 | 45.31 | -14.62 | -27.51 | 3.29 | -- | 0.2242 | -- | 137.01 | 226.43 | 74.45 | -- | 31.38 | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.58bn | 687.99m | 11.23bn | 8.26k | 16.62 | 1.58 | -- | 1.71 | 0.2665 | 0.2665 | 2.54 | 2.80 | 0.6617 | 2.57 | 4.70 | 796,529.00 | 7.13 | 8.51 | 9.65 | 12.74 | 51.88 | 58.64 | 10.77 | 14.12 | 1.38 | -- | 0.0532 | 41.54 | -3.23 | -0.7594 | 5.21 | -- | 1.57 | -- |
| Chengdu Easton Biopharmaceuticals Co Ltd | 1.33bn | 241.37m | 11.37bn | 1.52k | 46.91 | 3.97 | -- | 8.55 | 1.37 | 1.37 | 7.55 | 16.23 | 0.3809 | 1.83 | 5.89 | 873,161.50 | 6.92 | 8.09 | 8.44 | 9.82 | 71.90 | 81.72 | 18.16 | 20.10 | 3.12 | -- | 0.0444 | 30.37 | 20.82 | 7.34 | 5.15 | 17.01 | 4.24 | -- |
Data as of Feb 13 2026. Currency figures normalised to Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
6.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 10.87m | 3.44% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 2.82m | 0.89% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 2.55m | 0.81% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 1.31m | 0.42% |
| JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 2025 | 1.26m | 0.40% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 588.93k | 0.19% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 586.31k | 0.19% |
| Truvalue Asset Management Co. Ltd.as of 30 Jun 2025 | 571.99k | 0.18% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 523.74k | 0.17% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2025 | 512.00k | 0.16% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
